(28:54) 3 Episode 3 - Episode 3: Approaching the Treatment of NASH Holistically With Multispecialty Collaboration and Patient Education (17:01) By Clinical Content Hub × ...

Fatty liver disease, also known as hepatic steatosis, has become a widespread health concern ... to more severe conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and ...

Non-Alcoholic Fatty Liver Disease (NAFLD) is emerging as a significant global health concern, driven by increasing rates of ...

While simple steatosis may be clinically stable, nonalcoholic steatohepatitis (NASH) can be progressive. Inflammation is believed to be the driving force behind NASH and the progression to ...

Can-Fite’s drug candidate, Namodenoson, has been shown to reduce hepatic steatosis, inflammation, and fibrosis, as well as body weight reduction, in a Phase IIa clinical study where data have ...

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Viscient Biosciences ("Viscient") today announced that its scientists, along with collaborators from University of California, San Diego, ...

Also, liver fibrosis improved by at least one stage without a worsening of nonalcoholic fatty liver disease (NAFLD) activity in 24%, 26%, and 14%, respectively (P =0.0002 and P <0.0001 for the ...

“A phase 1b-2a study involving patients with NASH did not show safety concerns and suggested that pegozafermin therapy may improve hepatic steatosis, markers of inflammation and fibrosis ...

The net effect of CD8+ T cells on liver fibrosis may depend on the stage of the disease. They may have a NASH-driving role in early disease by increasing insulin resistance and hepatocyte damage.

Inclusion criteria were NASH fibrosis stage F2 or F3 and a nonalcoholic fatty liver disease activity score of at least 4, with at least one point for steatosis, ballooning, and lobular inflammation.

The technology LIVERFASt (Fibronostics) is a blood test for detecting and staging the fibrosis (scarring), activity (inflammation) and steatosis (fat build-up) of the liver. It can be used to help ...

They showed the efficacy of TOTUM•448 on hepatic steatosis and inflammation and suggested an improvement in certain markers of fibrosis, the first three stages of the development of these diseases.